The payoff for Celgene is distant, too. A series of missteps, notably the refusal-to-file letter for ozanimod, have tarnished the big biotech’s image, raising questions …
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify …
SPONSORED: 10 stocks we like better than Celgene When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the …
The stock’s 52-week high is $21.68. Volume totaled around 6 million, about 20% …
IK-> The technicals for CELG ($78.95 down $1.05) are bearish with a downward trend. The stock is below recent support. Look at the June 65/70 bull-put spread for a 20-cent credit. That's a 4.2% return and the stock has to fall by 11.3% to …
As a result of these false statements and/or omissions, the price of Celgene stock was artificially inflated during the …
Watch! After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
Stock futures are marginally higher this morning ... meetings from PYPL (after just announcing a $2.2b purchase of IZettle), chip darling MU, and CELG, which boasts one of the uglier charts in large-cap biotech land. There are also two huge …
One day after Celgene's stock hit a four-year low, the big biotech inked a drug discovery deal with Germany's Evotec. Evotec will use its preclinical discovery and development platform — including its phenotypic screening platform and …